News headlines about BioCryst Pharmaceuticals (NASDAQ:BCRX) have trended somewhat negative recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. BioCryst Pharmaceuticals earned a news impact score of -0.04 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.3555334055216 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern’s scoring:
BCRX stock traded down $0.08 during trading on Friday, hitting $4.60. The company had a trading volume of 827,123 shares, compared to its average volume of 835,360. The company has a market capitalization of $461.92, a PE ratio of -5.90 and a beta of 2.71. BioCryst Pharmaceuticals has a 52-week low of $3.95 and a 52-week high of $7.45. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.68 and a quick ratio of 1.68.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.06). The company had revenue of $3.89 million during the quarter, compared to analysts’ expectations of $6.07 million. BioCryst Pharmaceuticals had a negative return on equity of 106.53% and a negative net margin of 261.18%. The company’s quarterly revenue was down 56.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.06) EPS. sell-side analysts forecast that BioCryst Pharmaceuticals will post -0.79 EPS for the current fiscal year.
Several equities research analysts have recently weighed in on BCRX shares. Barclays started coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, December 20th. They issued an “equal weight” rating and a $6.00 target price on the stock. Royal Bank of Canada raised shares of BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a research note on Tuesday, January 2nd. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, January 23rd. BidaskClub raised shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, February 8th. Finally, ValuEngine downgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 14th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. BioCryst Pharmaceuticals currently has an average rating of “Hold” and an average price target of $8.29.
ILLEGAL ACTIVITY WARNING: “Somewhat Critical News Coverage Somewhat Unlikely to Affect BioCryst Pharmaceuticals (BCRX) Share Price” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/somewhat-critical-news-coverage-somewhat-unlikely-to-affect-biocryst-pharmaceuticals-bcrx-share-price.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.